206 related articles for article (PubMed ID: 19369910)
1. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation.
Zuo L; Luo X; Krystal JH; Cramer J; Charney DS; Gelernter J
Pharmacogenet Genomics; 2009 Jun; 19(6):437-46. PubMed ID: 19369910
[TBL] [Abstract][Full Text] [Related]
2. Association study of DTNBP1 with schizophrenia in a US sample.
Zuo L; Luo X; Kranzler HR; Lu L; Rosenheck RA; Cramer J; van Kammen DP; Erdos J; Charney DS; Krystal J; Gelernter J
Psychiatr Genet; 2009 Dec; 19(6):292-304. PubMed ID: 19862852
[TBL] [Abstract][Full Text] [Related]
3. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
4. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment.
Hwang R; Shinkai T; Deluca V; Macciardi F; Potkin S; Meltzer HY; Kennedy JL
Eur Neuropsychopharmacol; 2006 May; 16(4):248-59. PubMed ID: 16278074
[TBL] [Abstract][Full Text] [Related]
6. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene.
Duan J; Martinez M; Sanders AR; Hou C; Burrell GJ; Krasner AJ; Schwartz DB; Gejman PV
Hum Hered; 2007; 64(2):97-106. PubMed ID: 17476109
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
8. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
[TBL] [Abstract][Full Text] [Related]
9. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.
Rosenheck R; Chang S; Choe Y; Cramer J; Xu W; Thomas J; Henderson W; Charney D
J Clin Psychiatry; 2000 May; 61(5):382-6. PubMed ID: 10847315
[TBL] [Abstract][Full Text] [Related]
10. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.
Hwang R; Shinkai T; De Luca V; Müller DJ; Ni X; Macciardi F; Potkin S; Lieberman JA; Meltzer HY; Kennedy JL
Psychopharmacology (Berl); 2005 Aug; 181(1):179-87. PubMed ID: 15830237
[TBL] [Abstract][Full Text] [Related]
11. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.
Rosenheck R; Evans D; Herz L; Cramer J; Xu W; Thomas J; Henderson W; Charney D
Schizophr Bull; 1999; 25(4):709-19. PubMed ID: 10667741
[TBL] [Abstract][Full Text] [Related]
12. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
14. Dysbindin genotype and negative symptoms in schizophrenia.
DeRosse P; Funke B; Burdick KE; Lencz T; Ekholm JM; Kane JM; Kucherlapati R; Malhotra AK
Am J Psychiatry; 2006 Mar; 163(3):532-4. PubMed ID: 16513878
[TBL] [Abstract][Full Text] [Related]
15. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
16. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Lawson W; Crayton J; Cramer J; Xu W; Thomas J; Stolar M; Charney D
Biol Psychiatry; 1998 Sep; 44(6):475-82. PubMed ID: 9777179
[TBL] [Abstract][Full Text] [Related]
17. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.
Krakowski M; Tural U; Czobor P
Am J Psychiatry; 2021 Mar; 178(3):266-274. PubMed ID: 33472389
[TBL] [Abstract][Full Text] [Related]
19. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA
J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671
[TBL] [Abstract][Full Text] [Related]
20. Clozapine compared with haloperidol for refractory schizophrenia.
Birkett DP
N Engl J Med; 1998 Jan; 338(4):267-8. PubMed ID: 9441246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
